Highlights

  • Telix Pharmaceuticals reported H1 2026 group Revenue of US$477 million, up 22% year-over-year, tracking toward the upper end of full-year guidance
  • Adjusted EBITDA for H1 2026 was US$52 million, up 146% year-over-year, aided by an initial non-refundable payment of US$40 million from a Regeneron collaboration
  • Group gross Margin was 55%, up 2 percentage points year-over-year, while Precision Medicine gross margin was 65%
  • Research and development Investment for the half was US$124 million, directed primarily toward late-stage therapeutic and precision medicine programs

Telix Pharmaceuticals Limited (ASX:TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company advancing targeted theranostics for cancer. This article reviews the company's results for the half year ended 30 June 2026, its core operations, sector context and pipeline developments shareholders are monitoring for the remainder of 2026.

The share price was AUD 17.45 during the Trading session on 17 September 2026. The stock moved up by 3.44% during the trading session on 17 September 2026.

Company Business

Telix Pharmaceuticals develops and commercialises theranostic products, which pair a precision diagnostic agent with a targeted therapy to both diagnose and treat disease. The company's commercial Franchise is anchored by its prostate cancer imaging portfolio, including Illuccix, a kit for the preparation of gallium-68 gozetotide injection commercially available in 22 countries including the United States, and Gozellix, a related product approved by the U.S. Food and Drug Administration. Telix's late-stage therapeutic pipeline includes three investigational Assets in pivotal-stage trials: TLX591-Tx for prostate cancer, TLX101-Tx for recurrent glioblastoma, and TLX250-Tx for kidney cancer, supported by a broader pipeline of earlier-stage candidates. The company is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific.

Sector Context

The radiopharmaceutical and theranostics sector is shaped by regulatory approval pathways in major markets including the United States, Europe and Australia, the availability and Supply chain for radioactive isotopes used in diagnostic and therapeutic products, and reimbursement settings for nuclear medicine procedures. Companies in this sector rely on specialised Manufacturing and distribution networks given the short shelf life of many radiopharmaceutical products. Collaboration and licensing arrangements with larger pharmaceutical and biotechnology companies are also a feature of the sector, supporting the funding and commercialisation of late-stage pipeline assets.

Recent Developments

Telix Pharmaceuticals released its results for the half year ended 30 June 2026 on 20 August 2026, having advised on 31 July 2026 that the results would be released on that date. During the half, the company recognised an initial non-refundable payment of US$40 million from a collaboration with Regeneron, contributing to the increase in adjusted EBITDA for the period. The company's commercial portfolio continued to expand, with Illuccix commercially available in 22 countries and Gozellix holding FDA approval, alongside continued progress on its late-stage pivotal trials for TLX591-Tx, TLX101-Tx and TLX250-Tx.

Financial Performance

For H1 2026, Telix reported group revenue of US$477 million, up 22% year-over-year, tracking in line with the upper end of full-year guidance of US$950 million to US$970 million. Group gross margin was 55%, up 2 percentage points year-over-year, while Precision Medicine segment gross margin was 65%, up 1 percentage point, which the company attributed to solid commercial performance, favourable product mix and operational efficiencies. Adjusted EBITDA was US$52 million, up 146% year-over-year, reflecting strong Demand across the company's product portfolio and the initial non-refundable payment from the Regeneron collaboration. Research and Development investment for the half was US$124 million, directed primarily toward advancing late-stage therapeutic and precision medicine programs.

Risks to Consider

Telix's Business is subject to risks including regulatory approval outcomes for its late-stage pivotal trials and pipeline candidates, and the successful continued commercialisation of approved products such as Illuccix and Gozellix. The company's reliance on specialised radiopharmaceutical manufacturing and supply chains introduces operational risk, given the time-sensitive nature of these products. Revenue concentration in prostate cancer imaging products, competitive dynamics in the broader theranostics market, and execution risk associated with expanding into new therapeutic areas and geographies are additional factors relevant to the business. The company's collaboration arrangements, including with Regeneron, are also subject to the terms and milestones of those agreements.

What to Watch Next

Telix has reiterated full-year 2026 revenue guidance of US$950 million to US$970 million following its H1 2026 results. Shareholders are monitoring further progress on the company's pivotal-stage trials for TLX591-Tx, TLX101-Tx and TLX250-Tx, continued commercial rollout of its approved imaging products, and developments under its collaboration with Regeneron. Company representatives are scheduled to present at industry investor conferences in September 2026, and the company's full-year 2026 results represent the next major scheduled financial disclosure.

Key Insights

Telix Pharmaceuticals' H1 2026 results reflect continued double-digit revenue growth and a substantial increase in adjusted EBITDA, supported by both commercial performance and collaboration income. The company's expanding commercial portfolio and late-stage pipeline of therapeutic candidates remain central to its growth strategy. Progress on regulatory milestones and continued execution of its commercial and research and development programs are likely to remain key factors in the company's future reporting.